Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

STRATA Skin Sciences (SSKN) Total Current Liabilities (2016 - 2025)

STRATA Skin Sciences' Total Current Liabilities history spans 14 years, with the latest figure at $15.0 million for Q3 2025.

  • For Q3 2025, Total Current Liabilities rose 14.19% year-over-year to $15.0 million; the TTM value through Sep 2025 reached $15.0 million, up 14.19%, while the annual FY2024 figure was $13.4 million, 10.04% up from the prior year.
  • Total Current Liabilities for Q3 2025 was $15.0 million at STRATA Skin Sciences, up from $12.6 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $20.1 million in Q1 2021 and bottomed at $11.3 million in Q2 2024.
  • The 5-year median for Total Current Liabilities is $13.4 million (2024), against an average of $13.8 million.
  • The largest YoY upside for Total Current Liabilities was 19.65% in 2021 against a maximum downside of 34.94% in 2021.
  • A 5-year view of Total Current Liabilities shows it stood at $12.8 million in 2021, then increased by 4.87% to $13.4 million in 2022, then fell by 9.33% to $12.2 million in 2023, then grew by 10.04% to $13.4 million in 2024, then grew by 12.22% to $15.0 million in 2025.
  • Per Business Quant, the three most recent readings for SSKN's Total Current Liabilities are $15.0 million (Q3 2025), $12.6 million (Q2 2025), and $13.6 million (Q1 2025).